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The novel coronavirus, SARS-CoV-2, binds to target cells via the angiotensin-converting           
enzyme 2 (ACE2) receptor found in cells in blood vessels, lungs, heart, intestines, and kidneys. 
Type 2 diabetes (T2D) is a risk factor for acquiring SARS-Cov-2 infection and is associated with                
severe disease, acute respiratory distress syndrome and increased mortality (1). Diabetic patients            
have ACE2 overexpressed in kidney and the circulation; further, ACE2 expression may be             
increased in other tissues (for example in lungs) as a consequence of angiotensin-receptor             
blockers (ARBs), widely used in diabetic patients, potentially increasing susceptibility to           
SARS-Cov-2 infection. Previously, circulatory Renin-Angiotensin System (RAS) activity was         
described in the setting of sustained hyperglycemia in diabetes (2). Here, we hypothesized that              
acute normalization of glycemia would modulate RAS overactivation in T2D. Therefore, plasma            
RAS-related protein levels were determined in T2D versus controls (baseline) and after 1-hour             
hyperinsulinemic-euglycemic clamp (T2D).  
A case-control study of T2D and control subjects, approved by Yorkshire and Humber Research              
Ethics Committee. The clamp was performed as detailed previously (3); ​all patients underwent a              
10-hour fast prior to the clamp, but ad libitum water ingestion was encouraged. Patients were               
admitted 1-hour prior to the clamp procedure and remained in a supine position throughout              
the study. ​T2D: baseline glucose 7.6±0.4mmol/l (136.8±7.2mg/dl), reduced to 4.5±0.07mmol/l          
(81±1.2mg/dl) with 1-hour clamp. Controls: maintained at 4.9±0.1mmol/l (88.2±1.8mg/dl). Slow          
Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement (4) was used to           
determine RAS-related proteins: renin (REN), angiotensinogen (AGT) and ACE2. Statistical          
analysis performed using Graphpad Prism 8.0. T2D (n=23) and control (n=23) subjects were             
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matched for age (p=ns); T2D had higher BMI (p=0.0012); duration of disease 4.5±2.9 years              
(Table 1). Nine T2D subjects were treated with ACE inhibitor (ACEi) therapy. 
In T2D, total basal renin levels were elevated (1730±566 vs 675±72 RFU, T2D vs Control,               
p<0.05) (Figure 1A) whereas angiotensinogen levels were decreased (3786±174 vs 5005±574           
RFU, T2D vs Control, p<0.05) (Figure 1B). ACE2 levels did not differ between T2D and               
controls (291±31 vs 281±18 RFU, T2DM vs Control, p=ns) (Figure 1C). Acute normalization of              
hyperglycemia to euglycemia had no effect on levels of these RAS-related proteins (Figure 1A,              
B, C).  
RAS is overactivated in obesity (5) and the T2D subjects had higher BMI. To elucidate a                
potential relationship, T2D subjects (and Controls) were stratified into tertiles according to BMI;             
however, no trends in the protein levels were seen with increasing BMI in either group.               
Stratification of T2Ds into those treated or not with ACEi revealed no differences in basal               
RAS-related protein levels or in response to acute normalization of glycemia (ACEi vs             
non-ACEi: basal AGT 4106±228 vs 3580±235 RFU, normalized AGT: 4324±275 vs 4125±365            
RFU, p=ns ; basal REN 1358±258 vs 1969±923 RFU, normalized REN: 1250±207 vs 1903±843              
RFU, p=ns; basal ACE2 253±10 vs 317±50 RFU, normalized ACE2: 265±11 vs 299±48 RFU,              
p=ns) (Figure 1D, E, F).  
Of note, plasma glucagon levels were markedly elevated in patients with T2D compared to              
control (2458.9±291.3 vs 1460.8±135.6 RFU of glucagon, T2D vs Control, p< 0.01). 
This study showing elevated plasma renin, together with suppressed angiotensinogen and           
comparable levels of ACE2 protein, suggests RAS overactivation in T2D, independent of            
obesity, that was not corrected by acute normoglycemia. This suggests that immediate glucose             
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fluctuations do not modulate RAS and are therefore unlikely to modify SARS-CoV-2            
susceptibility.  
Renin causes conversion of angiotensinogen to angiotensin I (ANGI); ANGI is further converted             
by ACE to ANGII. ACE2, by contrast, converts ANGII to ANG-1-7, a peptide beneficial in               
maintaining normotension. ANGII receptor blockers, such as Losartan, increase ACE2 levels           
whereas ACE inhibitors do not affect ACE2 levels or activity. In addition, both ACEis and               
ARBs increased plasma renin activity (PRA), but not the plasma renin concentration, in healthy              
individuals and patients with hypertension, though the mechanism by which ACEi/ARB           
enhanced renin activity in humans has not yet been identified. However, glucagon stimulated             
plasma renin activity has also been reported in humans, and we found very high basal levels of                 
plasma glucagon in patients with T2D compared to controls, suggesting that the impact of ACEi               
therapy might be counteracted by glucagon in our study.  
A limitation of this study is the measurement of plasma proteins that may not reflect tissue level                 
expression. In addition, w​e report renin concentrations rather than activity that may be             
discrepant ​in some circumstances, including an underestimated renin activity in patients with            
liver cirrhosis and severe cardiac failure, whilst overestimated renin activity is seen with estrogen              
exposure. Notably, none of these conditions were present in the patients recruited to this study               
and the women were postmenopausal and not on hormone replacement therapy​.  
In conclusion, RAS protein levels differed between T2D and controls but were unaffected by              
glucose normalization, and no differences in plasma ACE2 levels were seen in ACEi-treated             
T2D subjects. This data supports the concept that discontinuing ACEi therapies in T2D subjects              
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Figure 1. ​Circulatory levels of renin-angiotensin system (RAS) related proteins in T2D.            
Plasma total renin (A), angiotensinogen (B) and ACE2 (C) levels in control subjects (open              
square) and subjects with T2D (black square). The basal level of plasma renin was higher and                
basal level of plasma angiotensinogen was lower in T2D compared to control. There was no               
change in the basal level of ACE2 in T2D. Acute normalization of glycemia had no effect on                 
levels of renin, angiotensinogen or ACE2 in T2D (A, B, C). Plasma levels of renin (D),                
angiotensinogen (E) and ACE2 (F) in T2D subjects who were not taking an ACEi              
antihypertensive drug (open square) and those who were on ACEi (black square). There was no               
effect of ACEi on basal levels or acute normalization levels of RAS related proteins in T2D.                
*p<0.05; ns = not significant.  
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